Redeye Interview – Magnus Corfitzen presents an update on Orviglance NDA and Financing
Magnus Corfitzen, CEO of Ascelia Pharma AB, discusses the NDA submission to the FDA for Orviglance and the recent SEK 30 million share issue Redeye Interview – 25 September 2025